Eurand received approval from the FDA for EUR-1048, to be marketed as GlaxoSmithKline’s Lamictal ODT (lamotrigine) Orally Disintegrating Tablets. Co-developed by Eurand and GSK, Lamictal ODT uses Eurand’s AdvaTab orally disintegrating tablet and Microcaps taste-masking technologies. Lamictal ODT is indicated for the long-term treatment of Bipolar I Disorder to lengthen the time between mood episodes in people 18 years or older, and is also used together with other medicines to tre...